Compare Invesco DB Oil Fund (DBO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Gilead Sciences, Inc. — how do they compare? Invesco DB Oil Fund trades at $24.04 (market cap $255.13M), while Gilead Sciences, Inc. trades at $151 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 714.9× Invesco DB Oil Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Gilead Sciences, Inc. for 111 Days on average.
| DBO | GILD | |
|---|---|---|
Market Cap | $255.13M | $182.40B |
Volume | 562,167 | 4,469,821 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $155.80 |
52-Week Low | $11.98 | $116.74 |
Typical Hold Time | 31 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
